Growth & profitability
- Revenue has grown 167.3% per year over the past 5 years.
Financial health
- The company is unprofitable; at its current free-cash-flow burn it has roughly 2.3 years of cash runway.
NMTC Financials NEUROONE MEDICAL TECHNOLOGIES Corp
15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $9M | -$4M | 56.5% | -46.5% | -$3M | — | $7M |
| 2024 | $3M | -$12M | 31.3% | -344.3% | -$11M | — | $1M |
| 2023 | $2M | -$12M | 23.4% | -612.3% | -$13M | — | $5M |
| 2022 | $171169 | -$10M | -41.4% | -5860.2% | -$8M | — | $8M |
| 2021 | $178146 | -$10M | -54.9% | -5735.9% | -$9M | — | $7M |
| 2020 | — | -$14M | — | — | -$4M | — | $4M |
| 2019 | — | -$7M | — | — | -$5M | — | $260749 |
| 2017 | — | -$5M | — | — | — | — | $26467 |
| 2016 | — | -$47775 | — | — | — | — | $522217 |
| 2015 | — | -$62863 | — | — | — | — | — |
| 2014 | — | -$36244 | — | — | — | — | — |
| 2014 | — | -$107308 | — | — | — | — | — |
| 2014 | — | -$101188 | — | — | — | — | — |
| 2014 | — | -$85169 | — | — | — | — | — |
| 2013 | — | -$30554 | — | — | — | — | — |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $2M | -$2M | 53.2% | -128.7% | -$1M | — | $3M |
| Dec '25 | $3M | -$1M | 54.2% | -59.0% | -$3M | — | $4M |
| Sep '25 | $3M | -$2M | 55.8% | -50.0% | -$2M | — | $7M |
| Jun '25 | $2M | -$2M | 53.9% | -111.2% | — | — | $8M |
| Mar '25 | $1M | -$2M | 55.6% | -193.3% | -$59315 | — | $1M |
| Dec '24 | $3M | $2M | 58.9% | 52.3% | $183633 | — | $1M |
| Sep '24 | $272284 | -$3M | 51.8% | -1034.5% | -$3M | — | $1M |
| Jun '24 | $825776 | -$3M | 34.1% | -338.3% | -$2M | — | $2M |
| Mar '24 | $1M | -$3M | 28.3% | -209.5% | -$2M | — | $2M |
| Dec '23 | $977649 | -$3M | 27.2% | -346.8% | -$4M | — | $3M |
| Sep '23 | $741780 | -$3M | 26.1% | -426.6% | -$3M | — | $5M |
| Jun '23 | $629906 | -$3M | 38.7% | -557.3% | -$3M | — | $3M |
| Mar '23 | $466176 | -$4M | 6.8% | -749.9% | -$4M | — | $4M |
| Dec '22 | $114579 | -$2M | -10.7% | -1557.3% | -$4M | — | $5M |
| Sep '22 | $68788 | -$1M | -21.9% | -2035.5% | $951635 | — | $8M |
| Jun '22 | $32049 | -$3M | -20.0% | -8616.3% | -$3M | — | $10M |
| Mar '22 | $36584 | -$3M | -99.0% | -8363.8% | -$3M | — | $13M |
| Dec '21 | $33748 | -$3M | -38.8% | -8324.4% | -$3M | — | $16M |
| Sep '21 | $48336 | -$3M | -35.4% | -5470.3% | -$2M | — | $7M |
| Jun '21 | $40096 | -$3M | -54.5% | -7569.3% | -$2M | — | $9M |
Valuation over time
How the market has priced NMTC against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has fallen from 82.4× (Mar '23) to 3.1× (Jun '26).
P/S
Frequently asked questions
Is NMTC growing its revenue and profit?
Over the past 5 years, NEUROONE MEDICAL TECHNOLOGIES Corp's revenue has grown 167.3% per year. These are computed facts, not advice.
How much debt does NMTC have?
As of FY2025, NEUROONE MEDICAL TECHNOLOGIES Corp reported — of total debt against $7M of cash.
What is NMTC's profit margin?
In FY2025, gross margin was 56.5%, operating margin -46.5%, and net margin -39.6%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.